Find policies, billing codes, payers, states, and providers
Diagnostic Testing Of Iron Homeostasis & Metabolism
Customize your policy alerts
Sign up for all Oscar Health policy alerts
Know when Oscar Health releases new policies or updates existing guidance.
Monitor payer policy activity
Defines coverage criteria and limitations for laboratory testing of iron status (e.g., ferritin, transferrin saturation) for Oscar Health members; applies to providers submitting claims for these tests. Coverage is dependent on member benefits and applicable state/federal rules.
Coverage Criteria
Serum ferritin — Covered indications and frequency
Measurement of serum ferritin levels (no more than one test per month unless otherwise specified) MEETS CRITERIA when any of the following conditions apply:
Frequency overrides specified in separate nodes.
Overrides default monthly frequency for this indication.
Specific CKD frequency rules.
Serum transferrin saturation — Covered indications
Measurement of serum transferrin saturation MEETS CRITERIA when any of the following apply:
Covered: Serum transferrin saturation
Measurement of serum transferrin saturation MEETS CRITERIA in any of the following:
See Note 2 for first-degree relatives definition.
Not covered: Other indications
Lack of published literature showing benefit.
Not covered: Hepcidin testing
Although some studies discuss hepcidin utility in select disorders, routine clinical hepcidin testing is not covered.
Not covered: GlycA testing for transferrin monitoring
GlycA is an NMR-based inflammatory biomarker and is not supported for monitoring transferrin in clinical management.
Covered clinical criteria
Coverage and testing is guided by clinical context — tests are supported when used to evaluate, monitor, or guide treatment for suspected iron deficiency, iron overload, anemia management, CKD-related anemia, IBD, perioperative anemia, RLS, and monitoring during iron chelation or ESA therapy.
Supported by KDIGO, KDOQI, ECCO, ICCAMS, ASH, AASM
From ICCAMS and related guidance
KDIGO/KDOQI/ASH/ICCAMS/ECCO recommendations
Carbohydrate-deficient transferrin testing is explicitly excluded from this policy and is considered out of scope.
Measurement of serum ferritin or transferrin levels (including transferrin saturation) performed for indications not listed as covered in this policy DOES NOT MEET CRITERIA. Serum hepcidin testing, including immunoassays, and the use of GlycA testing to measure or monitor transferrin or other glycosylated proteins are specifically stated as not meeting criteria due to insufficient published evidence of clinical benefit.
A review of guidelines did not identify recommendations supporting the use of ferritin as a first-line screening test in asymptomatic individuals; therefore routine ferritin screening in asymptomatic persons is not supported by the evidence cited in this policy.
If there is a conflict between this policy and any applicable government coverage determination (e.g., NCD/LCD or state Medicaid), the government policy supersedes this policy and will be used to make coverage determinations for affected members.
Tests that do not meet the policy's coverage criteria include measurement of ferritin or transferrin outside the listed covered indications, serum hepcidin testing (including immunoassays), and GlycA-based monitoring of transferrin or other glycoproteins. These uses are considered not medically necessary under the evidence available to this policy.
Routine population screening for iron deficiency or iron deficiency anemia in asymptomatic pregnant individuals and in asymptomatic children aged 6–24 months is not supported by the USPSTF evidence (grade I—insufficient). The policy therefore does not support routine ferritin screening as a first-line test for these asymptomatic populations.
Covered Indications
inv-58: Serum ferritin testing — Covered for anemia, iron overload, family history, liver disease, HLH/Still disease, hypogonadism, CKD, iron therapy, RLS/PLMD, family history
Measurement of serum ferritin levels MEETS CRITERIA when any of the following clinical situations apply:
Default frequency: no more than one test per month unless specified below.
inv-59: Serum transferrin saturation testing — Covered for evaluation of iron overload and iron deficiency anemia
Measurement of serum transferrin saturation MEETS CRITERIA when any of the following clinical situations apply:
TSAT used alongside ferritin per guideline recommendations.
inv-60: Evaluation of iron overload in first-degree relatives of HH
Covered when examining relatives of confirmed hereditary hemochromatosis cases:
See policy Note 2 for first-degree relative definition.
inv-61: Evaluation of iron deficiency anemia
Covered when evaluating suspected iron deficiency anemia:
ICCAMS and other guidelines cite ferritin <30 ng/mL or TSAT <20% as diagnostic thresholds; consider higher ferritin cutoffs in inflammatory states.
inv-62: Individuals with RLS or PLMD
Covered when evaluating or managing restless legs syndrome (RLS) or periodic limb movement disorder (PLMD):
AASM guidance recommends testing and suggests treatment thresholds (eg, ferritin ≤75 ng/mL or TSAT <20% for supplementation; IV iron indicated when ferritin 75–100 ng/mL per consensus statements).
inv-63: Evaluation of suspected iron overload and deficiency and monitoring in multiple disorders
Covered for diagnostic evaluation, monitoring, and management in multiple disorders where iron status affects care:
Ferritin thresholds and TSAT interpretation vary with inflammation and comorbid conditions; consider adjunct tests (hepcidin, RET‑He, GDF‑15) in select contexts.
KDIGO, ASH, and specialty guidance provide monitoring intervals.
inv-64: Evaluation and management contexts (anemia, chelation monitoring, perioperative, CKD, IBD, RLS)
Covered in clinical contexts where specialty guidelines inform testing and monitoring:
ICCAMS, ECCO, and perioperative consensus recommend ferritin and TSAT as core tests.
KDIGO recommendations (including 2024 update).
See ASH and KDIGO for intervals (eg, monthly during initial iron therapy; every 3–6 weeks during chelation).
inv-65: Diagnostic evaluation supported by guideline literature
Diagnostic evaluation supported by guideline literature:
References include WHO ferritin guidance, ICCAMS, ASH, KDIGO, ECCO and perioperative consensus statements.
inv-66: Clinical indications referenced in guideline literature (pregnancy, children, CKD, IBD, perioperative, cancer, RLS)
Clinical indications referenced in guideline literature include assessment of iron deficiency and iron overload in these settings:
Guidelines cited in evidence support these clinical contexts for ferritin/TSAT testing.
Frequency Limits and Monitoring Intervals
Procedure and Proprietary Codes
| 82728 | Ferritin |
| 83540 | Iron |
| 84466 | Transferrin |
| 0024U | Glycosylated acute phase proteins (GlycA), nuclear magnetic resonance spectroscopy, quantitative Proprietary test: GlycA Lab/Manufacturer: Laboratory Corporation of America |
| 0251U | Hepcidin-25, enzyme-linked immunosorbent assay (ELISA), serum or plasma Proprietary test: Intrinsic Hepcidin IDx ™ Test Lab/Manufacturer: IntrinsicDx |
Provider Actions and Billing Guidance
Authorization contingent on member benefits
Coverage is subject to the member’s benefits and authorization/medical necessity rules at time of request; order tests only if the service is a covered benefit for that member.
- Coverage does not guarantee reimbursement; other mandates, contracts, or member documents may supersede policy.
- Providers must follow applicable authorization processes determined by member benefits and regulations.
Order tests only for covered indications; non‑criteria tests risk denial
Order ferritin and transferrin saturation (TSAT) only for indications that meet the policy (e.g., evaluation of iron deficiency anemia, evaluation of iron overload including first‑degree relative with HH, RLS/PLMD); tests that do not meet criteria (including serum hepcidin immunoassays and GlycA for transferrin monitoring) may be denied.
- Document the clinical indication clearly when ordering.
- Policy states measurement of ferritin/TSAT outside listed indications DOES NOT MEET CRITERIA.
No action specified
(No provider action specified in source text for this placeholder.)
Procedure codes listed in policy (reference)
Reference the procedure and proprietary codes in the policy when ordering and billing: 82728 (Ferritin), 83540 (Iron), 84466 (Transferrin), 0024U (GlycA, LabCorp), 0251U (Hepcidin‑25, IntrinsicDx).
- Procedure codes are provided as a reference; they may not be all‑inclusive.
Procedure code reference for ordering/billing
The listed CPT/HCPCS and proprietary codes are provided for ordering/billing reference; there are no explicit code‑level prior authorization rules stated in this policy excerpt.
- Procedure codes appearing in Medical Policy documents are included only as a general reference tool and may not be all‑inclusive.
No explicit prior authorization specified in policy excerpt
The policy excerpts do not state any explicit prior‑authorization requirements for iron metabolism testing; authorization needs are determined by member benefits and applicable regulations.
- Providers should verify prior authorization requirements through the member’s benefit plan or payer portal.
Consider TSAT and HFE genetic testing for suspected hereditary hemochromatosis
For suspected hereditary hemochromatosis, consider measuring transferrin saturation and, after documented abnormal TSAT or ferritin, consider genetic testing for common HFE mutations (e.g., C282Y, H63D) per clinical judgment.
- HEIRS study and background recommend genetic testing in patients with idiopathic increases in TSAT and/or SF.
IV iron preferred when oral iron is intolerable or absorption impaired
Use intravenous iron when oral iron is not tolerated or ineffective, or when absorption is likely impaired (for example, post‑bariatric surgery or active IBD with inflammation); select IV formulations that can replace deficits in 1–2 infusions when appropriate.
- IV iron recommended if ferritin does not improve after an oral iron trial or when oral absorption is compromised.
- Follow specialty guidance (AGA, ASH) for IV iron selection and use.
Oral iron first‑line; monitor therapy per guidelines
Oral iron is recommended as first‑line therapy for iron deficiency; monitor response with hemoglobin and ferritin per guideline timelines (reassess moderate–severe anemia in 2–4 weeks; ferritin re‑check 3–6 months after normalization or after supplement initiation).
- Hemoglobin should increase by 10–20 g/L by 4 weeks; it may take up to 6 months to replenish iron stores.
- Reassess ferritin and TSAT during initial therapy (monthly during initial treatment as specialty guidance dictates) and every 3 months once stable.
No action specified
(No provider action specified in source text for this placeholder.)
No step therapy requirements stated
No step therapy requirements are specified in the policy excerpts.
- Management sequencing guidance is provided by clinical guidelines (oral iron first‑line; IV iron in specific scenarios) but no payer step therapy mandate is stated.
Submit accurate documentation and coding to support claims
Providers must submit accurate documentation and appropriate coding to support coverage; failure to follow coding/billing guidelines or current reimbursement policies may result in claim denial or recoupment.
- Follow standard coding guidelines (CPT, ICD‑10, UB edits, CMS NCCI, etc.) when submitting claims.
- Maintain documentation that supports medical necessity for the ordered tests.
Document clinical indication supporting TSAT coverage
Document the clinical indication that supports one of the listed covered uses for TSAT (evaluation of iron overload in first‑degree relatives of confirmed HH, evaluation of iron deficiency anemia, or RLS/periodic limb movement disorder).
- Clearly state the clinical reason on the order and in the chart to support medical necessity.
Document ferritin and transferrin saturation results (and supporting labs)
When evaluating suspected iron overload or deficiency, document both ferritin and transferrin saturation (TSAT) results; in inflammatory conditions or CKD include supporting tests (e.g., CRP) as indicated by guidelines.
- Ferritin thresholds: low ferritin <30 ng/mL suggests deficiency; ferritin >200 ng/mL (women) or >300 ng/mL (men) warrants additional testing.
- Include TSAT and other relevant labs to interpret ferritin in inflammatory states.
Ensure LDT validation and CLIA documentation for proprietary tests
Laboratory‑developed tests (LDTs) must be validated and performed in‑house as high‑complexity tests under CLIA; FDA clearance is not required for clinical use, but labs must follow CLIA validation/documentation procedures.
- LDTs are regulated by CMS as high‑complexity tests under CLIA '88 and require laboratory validation.
- FDA approval/clearance is not currently required for clinical use of LDTs.
Reference listed CPT/HCPCS and proprietary codes when billing
When ordering and billing, reference the applicable CPT/HCPCS and proprietary procedure codes listed in this policy (82728, 83540, 84466, 0024U, 0251U).
- Procedure codes are provided for reference and may not be exhaustive; verify coding per current coding manuals and payer guidance.
No additional documentation requirements specified
The policy excerpts do not specify additional documentation requirements beyond standard medical record and coding documentation.
- If payer‑specific documentation or prior authorization is required, providers must follow those processes as communicated by the payer.
Denial risk for non‑criteria tests and coding errors
Claims may be denied or recouped if coding/billing guidelines or current reimbursement policies are not followed; measurement of hepcidin or GlycA for transferrin monitoring are listed as not meeting criteria and are at risk for non‑coverage.
- Tests not meeting criteria (e.g., hepcidin immunoassays, GlycA) may be denied.
- Ensure coding supports the documented medical necessity to reduce denial risk.
Follow‑up and document high ferritin thresholds suggesting overload
Ferritin levels above 200 ng/mL in women or 300 ng/mL in men with no signs of inflammatory disease should prompt additional testing and documentation; failure to follow up on suspected overload may affect management.
- Therapeutic phlebotomy is indicated when SF ≥1000 ng/mL with high TSAT per policy background.
Government coverage takes precedence when conflicting
If this policy conflicts with applicable government coverage (NCD/LCD or state Medicaid), the government policy supersedes this policy and may affect coverage determinations.
- Verify applicable Medicare/Medicaid coverage rules for the member’s state and plan when ordering tests.
Procedure codes in policy are reference only
Procedure codes listed in the Medical Policy are provided as a general reference and may not be all‑inclusive; verify code applicability and updates before billing.
- Confirm up‑to‑date CPT/HCPCS usage and any payer‑specific code requirements prior to claim submission.
Ordering Requirements and Clinician Responsibilities
Ordering contingent on benefits and regulations
Coverage and ordering depend on the member's benefit coverage and applicable state and federal regulations; ordering provider restrictions may apply per benefit or state law—verify before ordering.
Document a covered clinical indication when ordering
When ordering tests, document one of the covered clinical indications listed in the policy (e.g., anemia, suspected iron overload, family history of HH, or RLS) to support medical necessity.
Who should order and act on tests — involve relevant clinicians
Testing and management should involve clinicians who manage anemia and iron disorders (primary care, gastroenterology, hematology); IBD and oncology guidance inform use of IV iron and monitoring.
- Coordinate testing and treatment decisions with specialists as appropriate (e.g., GI for IBD, hematology for complex anemia).
Ordering requirements for proprietary tests
No explicit ordering clinician restrictions are specified in these excerpts; some proprietary tests may require ordering by or referral to the performing laboratory or manufacturer.
- Proprietary assays (e.g., GlycA, Hepcidin‑25) identify the performing lab/manufacturer and may have specific ordering requirements.
No specific ordering provider restrictions stated
No specific ordering provider restrictions are stated in the provided text; use the procedure codes in the policy for billing/reference and follow payer rules.
Not Covered / Exclusions
Carbohydrate-deficient transferrin testing is explicitly out of scope for this policy and should not be considered part of covered iron metabolism testing under this document.
Measurement of ferritin or transferrin levels, including transferrin saturation, for clinical indications not listed as covered in this policy does not meet criteria and may be denied. Providers should document a covered clinical indication when ordering these tests.
Serum hepcidin testing (including available immunoassays and proprietary assays) DOES NOT MEET CRITERIA and is not covered under this policy due to insufficient evidence of clinical benefit in routine diagnostic use.
Use of GlycA testing (an NMR-based glycoprotein acetylation marker) to measure or monitor transferrin or other glycosylated proteins DOES NOT MEET CRITERIA. The policy lists GlycA (code 0024U) among proprietary tests but does not support its use for transferrin monitoring.
Screening asymptomatic individuals with serum ferritin as a first-line test is not supported by identified guidelines. Routine screening of asymptomatic pregnant people or children 6–24 months for iron deficiency/anemia lacks sufficient evidence and is not covered as routine population screening.
Routine population screening for iron deficiency in asymptomatic pregnant people and certain pediatric age groups is not supported by USPSTF guidance (grade I—insufficient evidence) and therefore is not covered as a routine service under this policy.
This segment of the policy does not list additional tests or indications as explicitly not covered beyond those identified (hepcidin, GlycA, and ferritin/transferrin outside covered uses). Procedure codes are provided for reference.
Definitions and Terminology
Iron homeostasis is tightly regulated: dietary iron is absorbed by enterocytes and exported via ferroportin, where transferrin binds ferric iron for transport to erythroid precursors. Ferritin is the intracellular iron storage protein and an acute phase reactant, and hepcidin regulates systemic iron by inducing ferroportin degradation. This physiologic context underlies the policy's focus on targeted testing in diagnostic and monitoring scenarios rather than broad population screening.
Background and Scientific Rationale
Clinical guidance and evidence cited in this policy support targeted use of ferritin and transferrin saturation for diagnosing and managing iron deficiency, iron overload, anemia of chronic disease, and related conditions (for example, CKD, IBD, perioperative anemia, pregnancy, and restless legs syndrome). Key guideline sources include WHO ferritin guidance and specialty society recommendations referenced in the evidence section that inform covered indications and monitoring strategies.
The policy's covered indications and monitoring recommendations draw on multiple guideline documents and consensus statements (for example, WHO guidance on ferritin, international perioperative anemia consensus, and KDIGO/ICCAMS guidance for CKD and anemia management). These sources inform diagnostic thresholds and condition-specific monitoring intervals referenced elsewhere in the policy.
Specific clinical indications cited in the guideline literature that inform this policy include assessment of iron deficiency and iron overload in pregnancy, pediatric age groups, chronic kidney disease, inflammatory bowel disease, perioperative anemia management, cancer-associated anemia, and restless legs syndrome. These references are listed in the evidence section and underpin the policy's condition-based coverage approach.
Revision History
Original documentation created and governance approved.
Policy effective date set for implementation.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.